Immunome (IMNM) Current Leases (2019 - 2026)
Immunome's (IMNM) quarterly Current Leases came in at $63000.0 in Q4 2024, down 79.68% YoY from $310000.0 in Q1 2024, and down 75.49% on a QoQ basis from $257000.0 in Q3 2024.
Powered by 
Analysis
Immunome (IMNM) Current Leases (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 3 years of Current Leases data on file, last reported at $63000.0 in Q4 2024.
- Quarterly Current Leases fell 79.68% year-over-year to $63000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $63000.0 (down 79.68% YoY) and the FY2024 annual result came in at $63000.0, down 79.68% from the prior year.
- Current Leases fell to $63000.0 in Q4 2024, from $257000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $310000.0 in Q4 2023 to a low of $63000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Immunome | 3.03 Bn | 2.51 Bn | - | 152,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 152,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 257,000.00 |
| Dec 31, 2023 | 310,000.00 |
| Dec 31, 2019 | 239,000.00 |